Expression of the B-Myb transcription factor is upregulated during late G 1 phase of the cell cycle by an E2F-dependent transcriptional mechanism. B-Myb is speci®cally phosphorylated during S phase, suggesting that a cyclin-dependent kinase (Cdk) regulates its activity. Consistent with this notion, the S phase-speci®c cyclin A/Cdk2 was found previously to enhance B-Myb transactivation activity in cotransfected cells. In this study we provide evidence that B-Myb is a direct physiological target for cyclin A/Cdk2. We demonstrate that B-Myb is an in vitro substrate for cyclin A/Cdk2, but not for cyclin D1/Cdk4 or cyclin E/Cdk2. By mutating candidate Cdk2 phosphorylation sites, we show that B-Myb is phosphorylated at Thr447, Thr490, Thr497 and Ser581 by cyclin A/Cdk2 in vitro and that these sites are also phosphorylated in cycling U-2 OS cells. Inhibition of endogenous Cdk2 by dominant negative Cdk2 attenuated phosphorylation of Thr447, Thr490 and Thr497, but had no eect upon Ser581 modi®cation. B-Myb transactivation activity was signi®cantly reduced in a mutant containing amino acid substitutions at all four identi®ed cyclin A/Cdk2 sites and was constitutively low in Saos-2 cells where endogenous cyclin A/Cdk2 activity was unable to phosphorylate ectopically expressed B-Myb. These data indicate that phosphorylation by cyclin A/Cdk2 is directly involved in enhancing B-Myb transactivation activity and that levels of endogenous cyclin A/Cdk2 activity may contribute to cell line-speci®c B-Myb function.
Introduction
B-Myb belongs to a family of transcription factors that includes two other known members, A-Myb and cMyb (reviewed in Lyon et al., 1994; Saville and Watson, 1998) . c-myb is the cellular progenitor of the avian retrovirus oncogene v-myb (Gonda and Bishop, 1983; Klempnauer et al., 1983) . Unlike the other members of this family, B-myb is widely expressed. B-myb mRNA has been detected in all proliferating cell lines so far examined (Golay et al., 1991; Kamano et al., 1995; Lam et al., 1992; Nomura et al., 1988; Reiss et al., 1991) , however, its transcription is markedly cell cycle regulated. The induction of B-myb transcription is delayed until late G 1 following mitogen stimulation of quiescent cells, or after release of cells from M-phase nocodazole block (Golay et al., 1991; Lam et al., 1992; Reiss et al., 1991) , resulting in maximal B-myb levels being attained in early S phase (Robinson et al., 1996) . Consistent with this association, a decrease in B-myb expression parallels the reduction in proliferation of haemopoietic and neuroblastoma cell lines during dierentiation (Bies et al., 1996; Lam et al., 1992; Raschella et al., 1995) . B-myb expression also closely correlates with cellular proliferation during mouse embryogenesis (Sitzmann et al., 1996) . The B-myb promoter contains an E2F transcription factor binding site which is required for its cell cycle control through a transcriptional repression mechanism in G 0 and G 1 involving the p107 and p130 retinoblastoma-related proteins (Bennett et al., 1996; Lam et al., 1995; Lam and Watson, 1993) . Con®rmatioan that B-myb is a bona ®de E2F-regulated gene has been obtained in several studies. Thus, overexpression of E2F-1 resulted in the induction of endogenous B-myb expression (DeGregori et al., 1995) , moreover, B-myb transcription was found to be deregulated in primary cells that are de®cient in both p107 and p130 (Hurford et al., 1997; Mulligan et al., 1998) .
The fact that B-Myb expression is directed speci®cally to S phase implies that it plays a key role in transcription at this stage of the cell cycle, and a number of studies implicate B-Myb in regulation of cell cycle progression. On one hand, B-myb antisense oligonucleotides inhibit proliferation of myeloid and lymphoid haemopoietic cell lines and glioblastoma cells (Arsura et al., 1992l; Lin et al., 1994) and transfection of BALB/c 3T3 ®broblasts and neuroblastoma cells with B-myb antisense expression plasmids reduces cloning eciency (Raschella et al., 1995; Sala and Calabretta, 1992) . On the other hand, constitutive expression of B-myb prevents cell cycle arrest of serumdeprived BALB/c 3T3 ®broblasts (Sala and Calabretta, 1992) and IL-6 treated M1 myeloid leukemia cells (Bies et al., 1996) ; this eect may be cell line speci®c, since ectopic expression of B-myb does not prevent growth arrest of serum deprivd NIH3T3 and Swiss 3T3 ®broblasts (Robinson et al., 1996) or T98G glioblastoma cells (Sala et al., 1996a) . Moreover, ectopic expression of B-myb in certain cell lines is able to overcome a p107-or p53-mediated G 1 checkpoint, thereby promoting entry into S phase (Lin et al., 1994; Sala et al., 1996a) .
B-Myb can transactivate the promoters of a number of genes, many of which are involved in cell proliferation. These include c-myc (Nakagoshi et al., 1992) , DNA polymerase-a , HSP70 (Foos et al., 1993) , B-myb itself (Sala et al., 1996b) , cdc2 (Sala et al., 1997) and DNA topoisomerase II a (Brandt et al., 1997) . B-Myb also represses the promoters of type I collagen genes (Marhamati and Sonensheim, 1996) . In no case has it been demonstrated that B-Myb plays a physiologically important role in regulation of these genes, and it is yet unclear how B-Myb is able to in¯uence cell cycle progression. B-Myb transactivation activity is markedly cell typespeci®c (Tashiro et al., 1995) and in many instances does not require the presence of consensus Myb binding sites (MBS) in promoters (Foos et al., 1993; Nakagoshi et al., 1993; Sala et al., 1997; Watson et al., 1993) . Where MBS are lacking, transactivation may be mediated through a cryptic binding site or through an interaction with a bridging transcription factor.
We have previously observed that B-Myb is phosphorylated in a cell cycle-dependent manner, leading to the appearance of a hyperphosphorylated form of B-Myb with reduced electrophoretic mobility at the onset of S phase (Robinson et al., 1996) . This cell cycle dependence of B-Myb phosphorylation suggested that it may be mediated by an S phase cyclin-dependent kinase (Cdk), and its timing correlates with the kinetics of cyclin E/Cdk2 and cyclin A/Cdk2 activation (Hall and Peters, 1996) . In Sf9 insect cells, baculovirus mediated co-expression of cyclin A/Cdk2 was found to result in hyperphosphorylation of B-Myb (Robinson et al., 1996) . Overexpression of cyclin A or cyclin A/Cdk2 in U-2 OS, Saos-2 or CV-1 cells also resulted in hyperphosphorylation of ectopically expressed B-Myb, detected by a reduction in electrophoretic mobility (Lane et al., 1997; Sala et al., 1997; Ziebold et al., 1997) . Signi®cantly, the ability of B-Myb to transactivate transcription of responsive reporter genes in these cells was markedly enhanced by cotransfection of cyclin A (Ansieau et al., 1997; Lane et al., 1997; Sala et al., 1997; Ziebold et al., 1997) , suggesting that hyperphosphorylated B-Myb is an activated form of the protein.
In this paper we show that B-Myb is a speci®c substrate for cyclin A/Cdk2. Ectopically expressed BMyb was shown to be phosphorylated in intact U-2 OS cells at sites that are phosphorylated by cyclin A/Cdk2 in vitro, and we provide evidence that Cdk2 activity is required for phosphorylation of at least some of these sites in vivo. The major cyclin A/Cdk-2 phosphorylation sites were identi®ed and shown to be important for functional activation of B-Myb.
Results

B-Myb is a speci®c substrate for cyclin A/Cdk2 in vitro
We have previously shown that B-Myb encoded by a recombinant baculovirus vector undergoes a reduction in electrophoretic mobility due to phosphorylation when co-expressed in Sf9 insect cells with cyclin A and Cdk2 (Robinson et al., 1996) . In contrast, coinfection with baculoviruses encoding cyclin D1/Cdk4 and cyclin E/Cdk2 did not alter the electrophoretic mobility of B-Myb, however, the possibility that BMyb was phosphorylated without an overt change in mobility was not investigated. To extend these observations, we examined whether a puri®ed bacterially expressed B-Myb fusion protein, GST-B-myb, would act as an in vitro substrate for dierent combinations of cyclin/Cdks expressed in Sf9 cells which were matched for kinase activity towards the retinoblastoma protein, GST-Rb. Signi®cantly, GST-Bmyb was radiolabelled by incubation with [ 32 P]ATP and cell extracts containing cyclin A/Cdk2, but was not a substrate for either cyclin D1/Cdk4 or cyclin E/Cdk2 under these conditions (Figure 1a , upper panel) despite equal activity of each of these kinases towards GST-Rb (Figure 1a, lower panel) . GST-B-myb and GST-Rb were not phosphorylated by extracts made from uninfected Sf9 cells (Figure 1a) . Similar experiments showed that phosphorylation of GST-B-myb by Sf9 cell extracts required expression of both cyclin A and Cdk2 (Figure 1b, upper panel) . B-Myb was stoichiometrically phosphorylated under these conditions since all of the immunoreactive full length GST-B-myb migrated with reduced electrophoretic mobility (Figure 1b, lower panel) . The change in B-Myb electrophoretic mobility induced by cyclin A/Cdk2 in vitro is therefore analogous to that suered by endogenous BMyb during entry of cells into S phase (Robinson et al., 1996) and by ectopically expressed B-Myb in cells cotransfected with cyclin A (Lane et al., 1997; Sala et al., 1997; Ziebold et al., 1997) .
Tryptic phosphopeptides from in vivo labelled B-Myb comigrate with tryptic phosphopeptides from B-Myb phosphorylated in vitro by cyclin A/Cdk2
We and others have previously shown that hyperphosphorylation of ectopically expressed B-Myb by cotransfection with cyclin A is correlated with a marked increase in transcriptional transactivation activity (Lane et al., 1997; Sala et al., 1997; Ziebold et al., 1997) . It is not clear from these studies whether B-Myb is a direct target of cyclin A/Cdk2 in intact cells, or whether this kinase induces another activity which in turn phosphorylates B-Myb. Moreover, it is uncertain whether phosphorylation of B-Myb directly contributes to its activation or whether cyclin A/Cdk2 targets a co-factor and indirectly causes B-Myb activation. To address these questions, we sought ®rst to determine whether in vitro cyclin A/Cdk2 phosphorylation sites in B-Myb were also modi®ed in intact cells. Identi®cation of these sites would also allow us to mutagenize the modi®ed amino acids in order to assess their signi®cance in B-Myb transactivation function. U-2 OS cells were chosen for this study because we have previously shown in these cells that transiently transfected B-Myb activates transcription of a Mybresponsive promoter/reporter, pT81luc 3xA, and that cotransfection of cyclin A or cyclin A/Cdk2 enhances this activity (Lane et al., 1997) .
To obtain in vivo phosphorylated B-Myb suitable for phosphopeptide analysis, U-2 OS cells were transfectd with HA-tagged B-Myb alone or together with a dominant negative Cdk2 mutant (termed Cdk2DN), cyclin A or a combination of cyclin A and Cdk2. BMyb was immunoprecipitated with 12CA5 anti-HA antibody from B-Myb phosphorylated by cyclin A/Cdk2 in vitro or in untransfected U-2 OS cells was digested with trypsin and phosphopeptides were resolved in twodimensions on TLC plates. Four major phosphopeptides (spots 1, 2, 5 and 6) and around 17 minor phosphopeptides were present in maps of B-Myb phosphorylated by cyclin A/Cdk2 in vitro (Figure 3a) . B-Myb expressed in U-2 OS cells in the absence of exogenous cyclin A/Cdk2 also gave rise to multiple tryptic phosphopeptides, of which six (spots 1 through 6) comigrated with tryptic phosphopeptides derived from in vitro phosphorylated B-Myb ( Figure 3a compared to b). Comigration was con®rmed by mixing experiments (data not shown). It is notable that four of these common spots were the most intense in the in vitro labelled B-Myb maps, and presumably represent the major cyclin A/Cdk2 phosphorylation sites. This strongly suggests that BMyb is modi®ed in cycling cells at sites which can be phosphorylated directly by cyclin A/Cdk2. Phosphorylation at three of these sites (spots 1, 2 and 5) was inhibited by cotransfection of U-2 OS cells with Cdk2DN ( Figure 3b compared to c), consistent with modi®cation being mediated by endogenous Cdk2. No other spots were reduced in intensity by Cdk2DN cotransfection, including three (spots 3, 4 and 6) which comigrated with phosphopeptides from in vitro phosphorylated B-Myb. Phosphorylation corresponding to these latter spots can therefore likely be mediated by a kinase other than Cdk2, although it is possible that they represent high anity sites that can be phosphorylated by residual Cdk2 activity in Cdk2DN transfected cells.
Although cotransfection of cyclin A or cyclin A/ Cdk2 enhances B-Myb transactivation activity in U-2 OS cells (Lane et al., 1997) , this did not result in the appearance of new phosphopeptides ( Figure 3b compared to d and e). It is notable, however, that the relative intensity of spots 1 ± 6 was increased, particularly by cyclin A/Cdk2, suggesting that it is the increased stoichiometry of phosphorylation at these sites that parallels the enhancement of B-Myb transcriptional activity. B-Myb is phosphorylated at Thr447, Thr490, Thr497, and Ser581 by cyclin A/Cdk2 in vitro and in cycling U-2 OS cells B-Myb contains 22 sites with the minimum speci®city for Cdk phosphorylation (Ser/Thr-Pro), and sucient spots were present in the phosphopeptide maps for BMyb to be phosphorylated by cyclin A/Cdk2 in vitro at all of these sites. As it would be extremely dicult to identify all phosphorylated residues in B-Myb, we chose to concentrate on characterizing the major in vitro-labelled phosphopeptides (spots 1 ± 6) which were common to B-Myb phosphorylated in U-2 OS cells. Three of these phosphopeptides (spots 1, 2 and 5) appeared to be the principal targets for Cdk2 in intact U-2 OS cells, as they were the only ones which were attenuated by Cdk2DN cotransfection (Figure 3c) .
A number of approaches were initially taken to identify candidate cyclin A/Cdk2 phosphorylation sites in B-Myb (data not shown). Maps obtained by cyclin A/Cdk2 phosphorylation in vitro were compared between full length GST-B-myb and GST fusion proteins containing discrete domains of B-Myb. The major phosphopeptides obtained in these studies were extracted from TLC plates and subjected to phosphoamino acid analyses. The mobility of these phosphopeptides was also compared to the predicted mobility (Boyle et al., 1991) of B-Myb tryptic phosphopeptides. In this way nine candidate amino acid residues were identi®ed and point mutations (Ser/Thr to Ala) made at each site. Wild-type and mutant GST-B-myb proteins were then phosphorylated in vitro by cyclin A/Cdk2, digested with trypsin, and analysed by twodimensional phosphopeptide mapping. Mutation of Thr447, Thr490 and Thr497 resulted in the loss of single spots (1, 2 and 5 respectively) from the phosphopeptide maps (Figure 4 ), whereas mutation of Ser581 resulted in the loss of three spots (3, 4 and 6). The generation of multiple tryptic peptides is probably due to Ser581 lying in a region of B-Myb containing multiple basic amino acids, as trypsin cleaves after Arg or Lys residues. Mutation of the other ®ve residues (Thr519, Thr522, Thr525, Thr542 and Thr617) had no discernible eect upon the phosphopeptide maps (data not shown).
The six phosphopeptides aected by these mutations all comigrated with phosphopeptides from B-Myb expressed in U-2 OS cells (spots 1 ± 6). Mutation of Thr447, Thr490 and Thr497 resulted in the loss of phosphopeptides which comigrated with the three Cdk2DN-sensitive spots, whereas the three spots which were unaected by Cdk2DN comigrated with To con®rm that these comigrating phosphopeptides were the same, U-2 OS cells were transfected with HAtagged wild-type B-Myb or a B-Myb derivative mutated at all four cyclin A/Cdk2 sites (Thr447, Thr490, Thr497 and Ser581; designated B-Myb/m4), and 32 P-labelled tryptic phosphopeptides derived from immunoprecipitated wild-type and mutant B-Myb were analysed by two-dimensional mapping. Mutation of the four putative cyclin A/Cdk2 sites was indeed found to result in the loss of all six comigrating phosphopeptides (Figure 5a compared to b) . These data show that B-Myb is phosphorylated in cycling U-2 OS cells at sites that can be phosphorylated directly by cyclin A/ Cdk2 (summarized in Figure 6 ).
The transactivation activity of B-Myb is directly dependent on its phosphorylation at cyclin A/Cdk2 sites
To determine whether mutation of individual or multiple cyclin A/Cdk2 sites compromised B-Mybdependent transcription, the appropriate mutants were tested by cotransfection assays in U-2 OS cells. As we have observed previously (Lane et al., 1997) , transfection of wild-type B-Myb activated transcription of the pT81luc 3xA promoter/reporter several-fold and this activity was substantially enhanced by cotransfection of cyclin A (Figure 7a ). Mutation of Thr447 or Ser581 signi®cantly decreased B-Myb transactivation activity, both in the absence and presence of exogenously expressed cyclin A. In contrast, B-Myb activity did not appear to be aected by mutation of Thr490 alone, and mutation of Thr497 had only a small eect ( Figure  7a) . Notably, mutation of all three Cdk2DN-sensitive sites (Thr447, Thr490 and Thr497 in mutant B-Myb/ m3) inhibited B-Myb transactivation activity to a greater extent than the single site mutations, and mutation of B-Myb at all four cyclin A/Cdk2 sites (BMyb/m4) had the largest eect, resulting in a 60% decrease in transactivation activity in the absence of exogenous cyclin A and a 75% decrease in activity in cells cotransfected with cyclin A (Figure 7a) . It is apparent, therefore, that mutation of multiple cyclin A/ Cdk2 sites on B-Myb renders it less responsive to activation by both endogenous kinase and exogenous cyclin A-dependent activity. These ®ndings imply that B-Myb transactivation function is, at least in part, dependent on direct modi®cation of B-Myb at cyclin A/Cdk2 sites, and that activity is cumulatively enhanced by phosphorylation at several sites.
Western blotting of transfected cell extracts demonstrated that the expression level of the B-Myb/T490A mutant, and also of B-Myb/T447A, B-Myb/m3 and BMyb/m4, was greater than that of wild-type B-Myb (Figure 7b ). The intrinsic activity of these mutant forms of B-Myb may consequently be lower than estimated in the transactivation assays. Higher expression levels of some of the phosphorylation site mutants may re¯ect an involvement of cyclin A/Cdk2 phosphorylation in promoting the turnover of B- Myb. Consistent with this, cotransfection of cyclin A decreased the expression of transiently transfected BMyb ( Figure 7b) ; the use of an anti-tag antibody makes it unlikely that reduction in the Western blot signal is due to changes in the immunoreactivity of the protein as a result of phosphorylation. It is notable that the characteristic B-Myb electrophoretic mobility shift obtained upon cotransfection of cyclin A with wild-type protein was still observed in the mutant BMyb proteins, even in B-Myb/m4 (Figure 7b ). This indicates that B-Myb can be phosphorylated at other sites in addition to those we have identi®ed. Phosphorylation at these other, perhaps less preferential sites, could be responsible for the residual (Figure 7a ).
The absence of phosphorylation of B-Myb at Cdk2DN-sensitive sites in Saos-2 cells correlates with low transactivation activity
Previous studies have shown that the ability of ectopically expressed B-Myb to stimulate transcription is markedly cell line-dependent (Tashiro et al., 1995) . Consistent with this, we observed that transcription of the pT81luc 3xA reporter was only increased to a very small extent by ectopic expression of B-Myb in Saos-2 cells (Figure 8a ) when compared to its activity in U-2 OS cells (Figure 7a ). As Saos-2 cells have been reported to contain low cyclin A levels (Sala et al., 1997), we used phosphopeptide mapping to investigate whether the relative inactivity of B-Myb in these cells was correlated with lack of phosphorylation at the major cyclin A/Cdk2 sites. This analysis demonstrated that B-Myb immunoprecipitated from 32 P-labelled Saos-2 cells in the absence of exogenous cyclin A lacked spots 1, 2 and 5 (Figure 8b ), which were labelled in U-2 OS cells in a Cdk2DN-sensitive manner ( Figure  3 ). Three spots (3, 4 and 6) resulting from phosphorylation at Ser581 were present in the Saos-2 phosphopeptide maps (Figure 8b/c) . As phosphorylation of Ser581 was not sensitive to Cdk2DN in U-2 OS cells (Figure 3 ), these ®ndings are consistent with Saos-2 cells containing reduced endogenous cyclin A/Cdk2 activity towards B-Myb compared to U-2 OS cells.
B-Myb-dependent transactivation of the pT81luc 3xA reporter was induced by the expression of ectopic cyclin A in Saos-2 cells (Figure 8a ). Under these circumstances spots 1 and 2, corresponding to peptides phosphorylated at Thr447 and Thr490, appeared in phosphopeptide maps of wild-type B-Myb (Figure 8c ) but not B-Myb/m4 (Figure 8d ). The fact that exogenous cyclin A is able to enhance B-Myb transactivation activity in Saos-2 cells indicates that other factors required for this activity are present, and it may be suggested that relative levels of phosphorylation of B-Myb at cyclin A/Cdk2-speci®c sites contributes to cell line-speci®c dierences in B-Myb function.
Discussion
We provide evidence that B-Myb is a physiological substrate for cyclin A/Cdk2. We show that B-Myb is a substrate for cyclin A/Cdk2 in vitro and that this results in phosphorylation of B-Myb at sites that are also phosphorylated in cycling U-2 OS cells. We identi®ed four sites (Thr447, Thr490, Thr497 and Ser581) that were phosphorylated both in vitro and in intact U-2 OS cells. Furthermore, we show that mutation of B-Myb at these sites impairs B-Myb B-Myb was found to be an in vitro substrate for cyclin A/Cdk2, but not for cyclin D1/Cdk4 or cyclin E/ Cdk2. This is consistent with the observation that hyperphosphorylated B-Myb is con®ned to S phase in synchronized cells (Robinson et al., 1996) . In contrast, Rb is phosphorylated by all three cyclin/Cdk combinations (Ewen et al., 1993; Kato et al., 1993) , although there are dierences in the sites of phosphorylation (Lundberg and Weinberg, 1998; . The kinase substrate speci®city of B-Myb resembles that of E2F-1 (Kitagawa et al., 1995 (Kitagawa et al., , 1996 Krek et al., 1994; Peeper et al., 1995) lamin B (Horton and Templeton, 1997) and Id3 (Deed et al., 1997 ). There appears to be no dierence between cyclin A/Cdk2 and cyclin E/Cdk2 consensus sequence requirements (Holmes and Solomon, 1996) . The speci®city shown by E2F-1 results from a stable interaction with cyclin A (Kitagawa et al., 1995; Krek et al., 1994) . We have been unable to detect a stable interaction between B-Myb and cyclin A (MKS and RJW, unpublished results), and it will be of interest to investigate further the basis for this speci®city.
The major B-Myb tryptic phosphopeptides generated by cyclin A/Cdk2 in vitro were phosphorylated at Thr447, Thr490, Thr497 and Ser581. Consistent with B-Myb being a direct substrate for cyclin A/Cdk2 in intact cells these sites were also phosphorylated in cycling U-2 OS cells and, excluding Thr497, in Saos-2 cells transfected with cyclin A. Furthermore, inhibition of endogenous Cdk2 by transfected Cdk2DN resulted in attenuation of phosphorylation at three of the major sites (Thr447, Thr490 and Thr497) in U-2 OS cells, indicating that phosphorylation at these sites occurs downstream of Cdk2. Cdk2DN did not detectably inhibit phosphorylation at any other site including Ser581 and it is possible a kinase with similar substrate speci®city to cyclin A/Cdk2 may be able to phosphorylate these residues. Consistent with this, Ser581 was phosphorylated in Saos-2 cells in the absence of exogenous cyclin A, under which circumstances endogenous cyclin A/Cdk2 was unable to phosphorylate the other three Cdk2 sites. This does not preclude a role for phosphorylation of Ser581 by Cdk2. Phosphorylation of this site by dierent kinases could provide a means for input of multiple signals into BMyb.
Cyclin A/Cdk2 phosphorylates preferentially the consensus sequence Ser/Thr-Pro-X-Lys/Arg. Two of the cyclin A/Cdk2 phosphorylation sites identi®ed in B-Myb, Thr447 (Thr Pro Val Lys) and Ser581 (Ser Pro Ile Lys), ®t this consensus sequence. B-Myb contains only one additional site, Thr524 (Thr Pro Phe Lys), which ®ts this consensus, however, we were unable to detect phosphorylation of this site by cyclin A/Cdk2 (data not shown). The remaining two sites we identi®ed in this study, Thr490 (Thr Pro Leu His) and Thr497 (Thr Pro Leu His), contain His three residues downstream of the site of phosphate incorporation. Peptides with either His, Ala, Cys or Pro at this position can be phosphorylated by cyclin A/Cdk2, although they are poorer substrates than peptides containing Lys or Arg (Holmes and Solomon, 1996) .
The extended phosphorylation sites containing Thr447, Thr490 and Ser581 in mouse B-Myb are completely conserved in the human, chicken and Xenopus laevis homologues. A residue corresponding to Thr497 in mouse B-Myb is also present in the homologous proteins, although in chickens and Xenopus the His three residues downstream of the site of phosphate incorporation is substituted by Leu. The relative spacing between individual sites has been maintained through evolution, and this degree of sequence conservation in such divergent species points to an essential role for the major cyclin A/Cdk2 phosphorylation sites in regulation of B-Myb activity. Studies using synthetic peptide substrates have revealed distinct preferences for sites phosphorylated by cyclin A/Cdk2 and cyclin D1/Cdk4 (Holmes and Solomon, 1996; Kitagawa et al., 1996) . Consistent with the inability of B-Myb to act as a cyclin D1/Cdk4 substrate in vitro, there is no site in B-Myb which precisely matches the consensus sequences for this kinase. It should be noted, however, that while some sites phosphorylated in pRb by cyclin D1/Cdk4 conform to the consensus, other phosphorylated sites do not .
The transactivation activity of B-Myb was compromised by mutation of the major cyclin A/Cdk2 phosphorylation sites. The simultaneous mutation of B-Myb at multiple phosphorylation sites had the largest eects. This indicates that the transactivation activity of B-Myb is directly dependent, at least in part, on phosphorylation by cyclin A/Cdk2 and that its activity is cumulatively enhanced by phosphorylation at multiple sites. It has previously been shown that the transactivatioan activity of ectopically expressed BMyb is markedly cell line-speci®c (Tashiro et al., 1995) . The low level of B-Myb transactivation activity in Saos-2 cells in the absence of exogenous cyclin/Cdk correlated with the absence of phosphorylation at speci®c Cdk2 sites. Our study thus raises the possibility that the ability of cells to phosphorylate B-Myb may account in part for dierences in its activity in dierent cell lines. We also observed that cotransfection of cyclin A was still able to enhance the transactivation activity of B-Myb mutated at all four sites to some extent. This could re¯ect the existence of unidenti®ed phosphorylation sites. Direct evidence for this is provided by the fact that B-Myb mutated at all four sites still underwent a decrease in electrophoretic mobility when cyclin A was overexpressed. Examination of phosphopeptide maps of the four site mutant did not reveal any obvious new exogenous cyclin Adependent phosphopeptides (data not shown). It is possible that phosphorylation at multiple minor sites could contribute to additional cumulative enhancement of B-Myb transactivation activity in cells cotransfected with cyclin A. We cannot exclude the possibility, however, that in addition to the eect of direct phosphorylation of B-Myb some of the eect of cyclin A/Cdk2 on B-Myb transactivation activity may be indirect, perhaps being mediated by a co-factor that regulates B-Myb function.
The precise mechanism by which phosphorylation of B-Myb enhances its transactivation activity has yet to be elucidated. C-terminal truncated forms of B-Myb are markedly more active than wild-type B-Myb and are far less responsive to ectopically expressed cyclin A (Lane et al., 1997; Ziebold et al., 1997) , suggesting that phosphorylation relieves inhibition mediated by a Cterminal negative regulatory domain (NRD). The BMyb C-terminus negatively in¯uences DNA binding activity (Bouwmeester et al., 1994; Watson et al., 1993) , however, we have been unable to detect any phosphorylation-dependent enhancement of B-Myb DNA binding activity (RJW, unpublished results) . It is notable that Ser581 maps within a nuclear localization signal and deletion of this region (amino acids 564 ± 584) partially impairs nuclear entry of BMyb (Nakagoshi et al., 1993) . Despite this ®nding, we have not observed any gross phosphorylation-dependent changes in the subcellular localization of B-Myb (Robinson et al., 1996) , moreover, previous studies indicate that mutation of Ser581 has no signi®cant eect upon the subcellular distribution of B-Myb (Takemoto et al., 1994) . The cyclin A/Cdk2 phosphorylation sites we identi®ed ( Figure 6 ) are located in or near the conserved region (CR: amino acids 468 ± 545), which has been reported to be required for B-Mybdependent transactivation (Nakagoshi et al., 1993) . Cell type-speci®c dierences in B-Myb transactivation function correlate with binding of as yet unidenti®ed proteins to the CR (Tashiro et al., 1995) , and it is therefore conceivable that cyclin A/Cdk2 phosphorylation could regulate this association. In this respect, it is of interest that Thr497 forms part of a consensus sequence for an ankyrin repeat which may be involved in these protein-protein interactions (Tashiro et al., 1995) . Our delineation of the B-Myb amino acids that are important for regulation of B-Myb activity by cyclin A, will aid in the identi®cation of putative coactivators whose binding is dependent upon phosphorylation at these sites.
The expression levels of B-Myb were increased by mutation of Cdk2 sites and decreased by cotransfection of cyclin A or cyclin A/Cdk2, suggesting that turnover of B-Myb is increased by phosphorylation. Mutation of Cdk phosphorylation sites has previously been shown to result in increased expression of a number of proteins, including p53 and RAG-2 (Lin and Desiderio, 1993) , p27Kip1 (Shea et al., 1997; Vlach et al., 1997) and thymidine kinase type 1 (Chang et al., 1998) in mammalian cells and Sic1p (Verma et al., 1997) and p65cdc18 (Jallepalli et al., 1997) in yeast, and in some cases this has been shown to be due to eects on protein turnover. C-terminally truncated forms of B-Myb display more transactivation activity than full-length (Ansieau et al., 1997; Lane et al., 1997; Ziebold et al., 1997) , and it may be hypothesized that the enhancement of B-Myb transactivation function by cyclin A/Cdk2 phosphorylation results from the generation of more active truncated forms. Counter to this possibility, no increase in the abundance of truncated forms of BMyb in cyclin A/Cdk2 cotransfected cells has been detected either by Western blotting or by EMSA (RJW, unpublished results), suggesting that these species are rapidly eliminated. An alternative view is that phosphorylation-dependent degradation of BMyb is important for limiting the half-life of the activated protein, thereby ensuring that functional BMyb is present only at the appropriate stage of the cell cycle (i.e. S phase). This may be particularly relevant in cycling cells, where B-Myb protein levels are less subject to control by E2F-dependent transcriptional mechanisms than in quiescent cells (Robinson et al., 1996) . Cyclin A is required for both entry into and passage through S phase (Girard et al., 1991; Pagano et al., 1992) . Our data support the contention that B-Myb, which has also been implicated in regulation of cell cycle progression, is a physiological target for cyclin A/Cdk2. B-Myb can be regulated at two levels by Cdks. The expression of B-Myb is regulated by the E2F family of transcription factors (Lam et al., 1995; Lam and Watson, 1993) , the activity of which is in¯uenced directly and indirectly by Cdk. B-Myb transactivatioan activity can be further enhanced through phosphorylation by cyclin A/Cdk2. Both of these mechanisms would act to increase B-Myb transactivation activity during S phase of the cell cycle, strongly implying that it is this stage where BMyb function is critical. Our identi®cation of the cyclin A/Cdk2 phosphorylation sites on B-Myb will facilitate further studies of the role of this transcription factor in cell cycle progression.
Materials and methods
Plasmids
The pT81luc 3xA reporter containing three MBS (representing the mim-1 A site) upstream of a minimal herpes simplex virus thymidine kinase promoter has been described previously (Ness et al., 1989; Nordeen, 1988) . To generate pcDNA3/B-myb, a pSVB-myb (Lane et al., 1997) EcoRI/HindIII DNA fragment containing the mouse Bmyb coding sequence was inserted into pcDNA3 (Invitrogen) using the equivalent sites. To generate pcDNA3/HABmyb, a DNA sequence encoding two copies of the in¯uenza hemagglutinin (HA) epitope recognized by monoclonal antibody 12CA5 was inserted into the N-terminal coding sequence of mouse B-myb in pcDNA3/B-myb using the polymerase chain reaction (PCR). Point mutations (Ser/ Thr to Ala) at candidate phosphorylation sites were generated by PCR in a GST/mouse B-myb fusion gene in the plasmid pGEX-2TB-myb. Correct introduction of all mutations was veri®ed by DNA sequencing. The mutated sequences were then subcloned from pGEX-2TB-myb into pcDNA3/HAB-myb. Plasmids encoding human cyclin A, Cdk2 and Cdk2DN under control of the cytomegalovirus immediate early promoter have been described previously (Hinds et al., 1992; van den Heuvel and Harlow, 1993) .
Cell culture
The human osteosarcoma cell lines U-2 OS and Saos-2 were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) containing 10% fetal bovine serum. Cells were plated at 60% con¯uence and transfected using the calcium phosphate precipitation technique as described previously (Lane et al., 1997) . For 60 mm dishes precipitates contained 5 mg of pT81luc 3xA and pSVbgal together with 3 mg of wild-type or mutant pcDNA3/HAB-myb, 0.3 mg of pCMVcyclin A, 0.3 mg of pCMVCdk2 and 1 mg of pCMVCdk2DN as indicated. For 100 mm dishes the amount of plasmids used was increased threefold. A balancing amount of empty pcDNA3 and pCMV vectors was added where necessary. Extracts for luciferase assays were made 36 ± 40 h after transfection as described previously . Extracts for Western blots were made simultaneously from cells transfected in parallel. Cells were washed twice with PBS and then lysed in electrophoresis sample buer (50 mM Tris pH 6.8, 2% SDS, 10% glycerol, 10 mM EDTA, 0.007% bromophenol blue). After sonication samples were stored at 7708C.
Western blot analysis
The protein concentrations of electrophoresis sample buer extracts were measured using the BCA protein assay (Pierce). After addition of DTT to a ®nal concentration of 100 mM, equal amounts of protein (20 mg) were analysed by Western blotting with polyclonal antibody B-176 raised to a region of mouse B-Myb encompassing the conserved region (amino acids 435 ± 558) or monoclonal antibody 12CA5 (Niman et al., 1983) which recognizes the HA epitope.
GST fusion protein preparation
Glutathione S-transferase protein expression and purification were carried out essentially as described (Kaelin et al., 1991) . Overnight cultures of E. coli BL21(DE3) transformed with pGEX-2T or pGEX-2T-B-Myb were diluted 1 : 10 with 500 ml 2xTY medium containing 100 mg/ml ampicillin. When the bacteria had reached an OD 600 of 0.8, isopropylthio-b-D-galactoside (IPTG) was added to a concentration of 0.5 mM and the bacteria incubated at 378C for 3 h. Cultures were pelleted by centrifugation at 3500 g for 15 min at 48C and resuspended in 7 ml of bacterial lysis buer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM DTT, 5 mM EDTA, 0.5% NP-40, with 10 mg/ml of the protease inhibitors pepstatin A, leupeptin, aprotinin, antipain and 5 mM benzamidine, 0.5 mM PMSF). The bacteria were lysed by mild sonication and centrifuged at 10 000 g for 10 min at 48C. Glycerol was added to the supernatant to a ®nal concentration of 10% and the supernatant stored at 778C. One ml of bacterial supernatant was incubated with 45 ml of glutathioneSepharose beads for 30 min. To prepare for in vitro kinase assays, the beads were washed twice with bacterial lysis buer and twice with buer K (50 mM HEPES, pH 7.5, 1 mM EGTA, 1 mM DTT, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 0.1 mM PMSF).
Expression of cyclin/Cdk in insect cells and in vitro kinase assay Spodoptera frugiperda Sf9 cells plated in 100 mm dishes were infected with baculoviruses (1.5 plaque forming units/ cell) encoding appropriate combinations of cyclin D1, cyclin E, cyclin A, Cdk4 and Cdk2 essentially as described previously (Parry et al., 1995) . Infected cells were harvested after 40 h and resuspended in 500 ml of buer K. Cells were lysed by incubation on ice for 10 min with occasional vortexing and centrifuged at 10 000 g for 10 min at 48C. For kinase assays, 15 ml GST/B-Myb substrates bound to glutathione-Sepharose beads (prepared as above) were resuspended in buer K to a ®nal volume of 35 ml and incubated with 5 ml of Sf9 cell lysates in the presence of 0.2 mM ATP, 1 mM MgCl 2 , and 5 mCi [g-32 P]ATP for 20 min at 308C. The reactions were terminated by addition of 500 ml of ice cold NP-40 lysis buer (50 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM DTT, 5 mM EDTA, 0.5% NP-40, 10 mM NaF, 10 mM sodium pyrophosphate, 10 mM bglycerophosphate, 2 mM Na 3 VO 4 with protease inhibitors 10 mg/ml of each pepstatin A, leupeptin, aprotinin, antipain, 5 mM benzamidine, 0.5 mM PMSF). The beads were pelleted by centrifugation and B-Myb eluted by addition of electrophoresis sample buer.
Phosphate labelling and two-dimensional tryptic phosphopeptide mapping Asynchronous U-2 OS or Saos-2 cells in 100 mm dishes (36 ± 40 h post transfection) were cultured in the presence of 3 ml of phosphate-free DMEM/10% FBS containing 0.3 mCi/ml [ 32 P]orthophosphate for 3 h. Cells were placed on ice, washed once with ice cold PBS then scraped into 1 ml of NP-40 lysis buer and lysed by incubation on ice for 20 min with occasional vortexing. Samples were centrifuged at 14 000 g for 15 min at 48C. The supernatant was precleared by incubation for 30 min with an irrelevant IgG2b antibody bound to protein G-Sepharose. The cleared supernatant was then incubated for 2 h with 12CA5 antibody bound to protein G-Sepharose. The immune complexes were washed three times with NP-40 lysis buer and eluted from the protein G-Sepharose with electrophoresis sample buer. A fraction of each sample was used for Western blotting and autoradiography to compare B-Myb expression with phosphate incorporation into B-Myb. The majority of the immunoprecipitate was used for two dimensional thin-layer chromatography (TLC) phosphopeptide mapping. Proteins were resolved by SDS ± PAGE using 7.5% polyacrylamide gels. B-Myb was localized by autoradiography of the wet gel, excized and treated essentially as described (Boyle et al., 1991) . BMyb was digested with (TPCK)-treated trypsin (Worthington), and the resulting phosphopeptides (matched for c.p.m.) were analysed by electrophoresis at pH 1.9 followed by ascending chromatography using phospho chromatography buer (Boyle et al., 1991) . Phosphorylated peptides were visualized by autoradiography or by phosphorimaging.
